EMA panel says FDA-approved drug is too risky

The EMA’s Committee for Medicinal Products for Human Use (CHMP) says that Portola Pharmaceuticals’ Dexxience, approved by the FDA in June 2017, had more episodes of bleeding than those treated with the comparator medicine.Original Article